Ilaria, P.; Nevena, S.; Ersilia, T.; Federica, T.; Felice, F.; Agnieszka Ewa, D.; Francesco, F.; Concetta, P.
Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty®) COVID-19 Vaccination Successfully Treated with Cemiplimab. Viruses 2024, 16, 1260.
https://doi.org/10.3390/v16081260
AMA Style
Ilaria P, Nevena S, Ersilia T, Federica T, Felice F, Agnieszka Ewa D, Francesco F, Concetta P.
Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty®) COVID-19 Vaccination Successfully Treated with Cemiplimab. Viruses. 2024; 16(8):1260.
https://doi.org/10.3390/v16081260
Chicago/Turabian Style
Ilaria, Proietti, Skroza Nevena, Tolino Ersilia, Trovato Federica, Forte Felice, Dybala Agnieszka Ewa, Fiorentino Francesco, and Potenza Concetta.
2024. "Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty®) COVID-19 Vaccination Successfully Treated with Cemiplimab" Viruses 16, no. 8: 1260.
https://doi.org/10.3390/v16081260
APA Style
Ilaria, P., Nevena, S., Ersilia, T., Federica, T., Felice, F., Agnieszka Ewa, D., Francesco, F., & Concetta, P.
(2024). Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty®) COVID-19 Vaccination Successfully Treated with Cemiplimab. Viruses, 16(8), 1260.
https://doi.org/10.3390/v16081260